TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12092301

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tegafur-uracil-folonic acid
Number of subjects: 4

Group type: COMPARATOR
Intervention: 5-FU with folonic acid
Number of subjects: 4
Study: 9650008

Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 7640969

Group type: EXPERIMENTAL
Intervention: Functional Standing Test (FST) administered by two testers
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Functional Standing Test (FST) administered to adolescents with SCI
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Functional Standing Test (FST) administered to able-bodied young adults
Number of subjects: 13
Study: 29747087

Group type: EXPERIMENTAL
Intervention: Dietary weight-loss intervention (very-low-calorie diet for 6 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No-weight loss control group
Number of subjects: 52
Study: 27034058

Group type: EXPERIMENTAL
Intervention: Protein-hydrolysed lactose-free milk
Number of subjects: 97

Group type: COMPARATOR
Intervention: Commercially available lactose-free milk
Number of subjects: 97
Study: 26672080

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 2202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2202

Group type: EXPERIMENTAL
Intervention: NCS patients
Number of subjects: 2202
Study: 23946328

Group type: EXPERIMENTAL
Intervention: CPOP-R (pixantrone-based regimen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHOP-R (doxorubicin-based therapy)
Number of subjects: 0
Study: 21058885

Group type: EXPERIMENTAL
Intervention: Biodanza intervention (n=27)
Number of subjects: 59
Study: 19635613

Group type: EXPERIMENTAL
Intervention: Bazedoxifene (20 or 40 mg) combined with conjugated estrogens (0.625 or 0.45 mg)
Number of subjects: 3397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3397
Study: 16911780

Group type: EXPERIMENTAL
Intervention: Email communication initiated by the clinic
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Health education provided via email
Number of subjects: 173
Study: 15181095

Group type: COMPARATOR
Intervention: Dihydrotestosterone (DHT) - daily transdermal, n = 17, for 3 months
Number of subjects: 75

Group type: COMPARATOR
Intervention: Recombinant human chorionic gonadotropin (rhCG) - subcutaneous, two injections weekly, n = 20, for 3 months
Number of subjects: 75
Study: 10886297

Group type: EXPERIMENTAL
Intervention: Cases (paternal history of CHD)
Number of subjects: 822
Study: 9290542

Group type: EXPERIMENTAL
Intervention: Nephrotoxic group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ischemic group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ischemic ATN with advancing age
Number of subjects: 0
Study: 8302148

Group type: EXPERIMENTAL
Intervention: High dose intravenous labetalol (1.0‐1.5 mg/Kg, repeated bolus of 10 mg/bolus)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No labetalol (Control group A)
Number of subjects: 14
Study: 3519693

Group type: EXPERIMENTAL
Intervention: Self-inspection group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Traditional group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 27879536

Group type: EXPERIMENTAL
Intervention: Mental health promotion program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 70
Study: 26314349

Group type: EXPERIMENTAL
Intervention: Silastic ring (WR)
Number of subjects: 400

Group type: COMPARATOR
Intervention: No silastic ring (NR)
Number of subjects: 400
Study: 24237300

Group type: EXPERIMENTAL
Intervention: Interferon-alpha lozenge 500 IU/day
Number of subjects: 169

Group type: COMPARATOR
Intervention: Interferon-alpha lozenge 1500 IU/day
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 22398262

Group type: EXPERIMENTAL
Intervention: Adding low level laser therapy (LLLT) to ultrasound (US) and exercise
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ultrasound (US) and exercise
Number of subjects: 42
Study: 20579370

Group type: EXPERIMENTAL
Intervention: Training in using the new measure and undertaking observations of designated residents (intervention condition)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Training in using the new measure (intervention condition)
Number of subjects: 80
Study: 18306449

Group type: EXPERIMENTAL
Intervention: 2 Hz EAS
Number of subjects: 62

Group type: COMPARATOR
Intervention: 120 Hz EAS
Number of subjects: 62
Study: 16011981

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (1.5 g daily for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (for 8 weeks)
Number of subjects: 20
Study: 12422137

Group type: EXPERIMENTAL
Intervention: Low-fat meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 20
Study: 10361382

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (180 mg orally)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg in an i.v. bolus injection)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Naloxone plus Pyridostigmine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: TRH plus Placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: TRH plus Naloxone
Number of subjects: 28

Group type: COMPARATOR
Intervention: TRH plus Pyridostigmine
Number of subjects: 28

Group type: COMPARATOR
Intervention: TRH plus Naloxone plus Pyridostigmine
Number of subjects: 28
Study: 7732443

Group type: EXPERIMENTAL
Intervention: Water-soluble, hyperosmolar, radiocontrast material via nasogastric tube on the third postoperative day
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group managed without radiocontrast material, received a suppository on the third day
Number of subjects: 115
Study: 2028630

Group type: EXPERIMENTAL
Intervention: Nimodipine 80 mg tid
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study: 7037504

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (betamethasone valerate or clobetasone butyrate)
Number of subjects: 10
Study: 30302838

Group type: EXPERIMENTAL
Intervention: Diabetes guidelines usage
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Knowledge of stroke as a diabetes-related complication
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Understanding of diabetes pathology
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Knowledge to advise on laboratory results
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Knowledge to improve outcomes through lifestyle changes
Number of subjects: 336

Group type: COMPARATOR
Intervention: Knowledge of stroke as a complication of type 2 diabetes
Number of subjects: 336

Group type: COMPARATOR
Intervention: Knowledge to advise on medications
Number of subjects: 336

Group type: COMPARATOR
Intervention: Knowledge of modifiable risk factors (hypertension, smoking, dyslipidaemia)
Number of subjects: 336
Study: 28005446

Group type: EXPERIMENTAL
Intervention: Agave tequilana Weber inulin (24g) with 500mL lemon water and 75g glucose
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo drink with 500mL lemon drink and 75g glucose
Number of subjects: 14
Study: 25620217

Group type: EXPERIMENTAL
Intervention: Second-look laparoscopy (SLL)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 216
Study: 25150117

Group type: EXPERIMENTAL
Intervention: MB-6
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 21479888

Group type: EXPERIMENTAL
Intervention: Experimental condition (n = 80) - received training and conducted 12 weeks of outreach
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control condition (n = 78)
Number of subjects: 158
Study: 19848199

Group type: EXPERIMENTAL
Intervention: Buxu Huayu Qutan Decoction (BHQD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study: 18001620

Group type: EXPERIMENTAL
Intervention: Folic acid therapy
Number of subjects: 0
Study: 15680021

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 85

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 85

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 85
Study: 11350538

Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9424404

Group type: EXPERIMENTAL
Intervention: House dust mite allergen (HDM) extract inhalation challenge in atopic asthmatics (AA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: House dust mite allergen (HDM) extract inhalation challenge in atopic non-asthmatics (AN)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: BAL fluid from AA
Number of subjects: 31
Study: 7708638

Group type: EXPERIMENTAL
Intervention: Aspirin test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood chemiluminescence (CL) tests with M. tuberculosis (BCG and staphylococcus strains)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood chemiluminescence (CL) tests with staphylococcus
Number of subjects: 0
Study: 2972170

Group type: EXPERIMENTAL
Intervention: Estrogen/gestagen replacement therapy
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Withdrawal of estrogen/gestagen replacement therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo group (implied control)
Number of subjects: 110
Study: 30395011

Group type: EXPERIMENTAL
Intervention: Full dose of quadrivalent, split‐virion, inactivated influenza vaccine (IIV4)
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Half dose of quadrivalent, split‐virion, inactivated influenza vaccine (IIV4)
Number of subjects: 1950

Group type: EXPERIMENTAL
Intervention: Full dose of IIV4
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Half dose of IIV4
Number of subjects: 1950
Study: 27348853

Group type: EXPERIMENTAL
Intervention: Remifentanil patient-controlled analgesia (RPCA)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Epidural analgesia (EA)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Remifentanil patient-controlled analgesia (RPCA) among those who received analgesia
Number of subjects: 408

Group type: COMPARATOR
Intervention: Epidural analgesia (EA) among those who received analgesia
Number of subjects: 408
Study: 26666295

Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) using Routine Outcome Monitoring (ROM) in intervention teams
Number of subjects: 364

Group type: COMPARATOR
Intervention: Usual decision making without specific SDM or ROM instructions in control teams
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) using Routine Outcome Monitoring (ROM)
Number of subjects: 364
Study: 23718142

Group type: EXPERIMENTAL
Intervention: SHK (heart-kidney)
Number of subjects: 1801

Group type: EXPERIMENTAL
Intervention: SHLi (heart-liver)
Number of subjects: 1801

Group type: EXPERIMENTAL
Intervention: SLuLi (lung-liver)
Number of subjects: 1801

Group type: EXPERIMENTAL
Intervention: SLuK (lung-kidney)
Number of subjects: 1801
Study: 21056689

Group type: EXPERIMENTAL
Intervention: 135 μg/wk peginterferon alfa‐2a for 48 weeks
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 90 μg/wk peginterferon alfa‐2a for 48 weeks
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 135 μg/wk peginterferon alfa‐2a for 48 weeks (among those with undetectable HCV RNA at week 12)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 90 μg/wk peginterferon alfa‐2a for 48 weeks (among those with undetectable HCV RNA at week 12)
Number of subjects: 85
Study: 19769705

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort) Maintenance And Reliever Therapy (Symbicort SMART)
Number of subjects: 908
Study: 16996784

Group type: EXPERIMENTAL
Intervention: Knowledge of risk factors in oral cancer; 100% identified tobacco as a risk factor.
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Knowledge of risk factors in oral cancer; 90% identified alcohol as a risk factor.
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Knowledge of risk factors in oral cancer; 50.7% identified sun exposure with labial cancer.
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Advice on prevention of oral cancer; 51.4% routinely gave advice to patients.
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Self-assessment of training; 57.1% did not consider themselves sufficiently trained to discover suspected oral cancer lesions.
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Perception of academic training; 84.3% recognized insufficient academic training on early diagnosis and prevention of oral cancer.
Number of subjects: 240
Study: 16871743

Group type: EXPERIMENTAL
Intervention: Hemodialysis (3 times per week, 4 hours per session, using Fresenius dialysers with polysulfone membranes and bicarbonate buffer with glucose)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (21 healthy volunteers)
Number of subjects: 42
Study: 12518005

Group type: EXPERIMENTAL
Intervention: Invitation to screening
Number of subjects: 77080
Study: 9516091

Group type: EXPERIMENTAL
Intervention: Aerosolized tobramycin 80 mg b.i.d. for 12 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 7747578

Group type: EXPERIMENTAL
Intervention: Conventional application of 1% cyclopentolate hydrochloride (30 microliters drops)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Inner canthus application of 1% cyclopentolate hydrochloride (30 microliters drops)
Number of subjects: 8
Study: 2701817

Group type: EXPERIMENTAL
Intervention: Intraoperative portal chemotherapy without blood transfusion
Number of subjects: 469

Group type: COMPARATOR
Intervention: Blood transfusions during curative resection
Number of subjects: 469
Study: 215985

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Neomycin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 30760138

Group type: EXPERIMENTAL
Intervention: Progressive osteoarthritis group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-progressive osteoarthritis group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Postoperative wrist osteoarthritis progression
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Postoperative morphological changes
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Radioscaphoid angle change
Number of subjects: 56
Study: 28719280

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) - one round
Number of subjects: 3612

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) - two rounds
Number of subjects: 3612
Study: 26011507

Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 15
Study: 23503379

Group type: EXPERIMENTAL
Intervention: Genetic therapy combined with traditional treatment (conservative means) in 39 patients.
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Genetic therapy combined with reconstructive vascular operations in 35 patients.
Number of subjects: 134

Group type: COMPARATOR
Intervention: Traditional treatment (control group) in 60 patients.
Number of subjects: 134
Study: 22375408

Group type: EXPERIMENTAL
Intervention: Respiratory exercises increases Chinese medicine
Number of subjects: 216

Group type: COMPARATOR
Intervention: Respiratory exercises increases placebo
Number of subjects: 216
Study: 18823290

Group type: EXPERIMENTAL
Intervention: JNJ-38488502 (0.42 mg kg(‐1) i.v. infusion)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: JNJ-38488502
Number of subjects: 23
Study: 17297424

Group type: EXPERIMENTAL
Intervention: Gene therapy strategies (including gene directed enzyme/pro-drug therapy, inhibition of oncogenes, restoration of tumor-suppressor genes, immunotherapy, anti-angiogenesis, and virotherapy)
Number of subjects: 0
Study: 15284373

Group type: EXPERIMENTAL
Intervention: 1.00 g protein/(kg. d)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.75 g protein/(kg. d)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.50 g protein/(kg. d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1.20 g protein/(kg. d) for 2 wk (HPro)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1.2 g protein/(kg. d) for 1 wk and then 0.50 g protein/(kg. d) for a 2nd week (IPro)
Number of subjects: 50
Study: 11510711

Group type: EXPERIMENTAL
Intervention: Computerised analysis of fetal heart rate patterns
Number of subjects: 679
Study: 9663533

Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 42

Group type: COMPARATOR
Intervention: Roller pump
Number of subjects: 42
Study: 7918934

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (3,000,000 units three times per week for at least six months)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pre-treatment
Number of subjects: 9
Study: 2701186

Group type: EXPERIMENTAL
Intervention: Anti-influenza vaccine
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 4918459

Group type: EXPERIMENTAL
Intervention: CIBA 34,647‐Ba (gamma aminobutyric acid derivative)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study: 31197991

Group type: EXPERIMENTAL
Intervention: Preoperative traction
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-preoperative traction
Number of subjects: 120
Study: 28314555

Group type: EXPERIMENTAL
Intervention: Levobupivacain injection (L group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Levobupivacain and magnesium sulfate injection (LM group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intra-articular saline injection (control group)
Number of subjects: 96
Study: 26165259

Group type: EXPERIMENTAL
Intervention: Continuous infusion through an On Q continuous infusion pump (On Q group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single shot popliteal sciatic nerve block (SSB group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: On Q group
Number of subjects: 50
Study: 23257347

Group type: EXPERIMENTAL
Intervention: Bimosiamose (10 mg) inhaled twice daily for 28 days
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo inhaled twice daily for 28 days
Number of subjects: 77
Study: 21939965

Group type: EXPERIMENTAL
Intervention: Auditory signal with certain visual information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambiguous pronunciation attributed to an external source
Number of subjects: 0
Study: 18306343

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT-BN)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Individual supportive psychotherapy (SPT)
Number of subjects: 80
Study: 16763797

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CaD) 2 g daily for 24 months
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CaD)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 194
Study: 15886245

Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg, twice daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12970658

Group type: EXPERIMENTAL
Intervention: Rigid fixation (n = 78)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Wire fixation (n = 49)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Rigid fixation with genioplasty (n = 35)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Wire fixation with genioplasty (n = 24)
Number of subjects: 127
Study: 10081536

Group type: EXPERIMENTAL
Intervention: Glucose 10%, 3 ml.kg‐1.h‐1 (300 mg.kg‐1.h‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Glucose-free fluid regime
Number of subjects: 18
Study: 7593729

Group type: EXPERIMENTAL
Intervention: Moclobemide 150 mg twice daily
Number of subjects: 270

Group type: COMPARATOR
Intervention: Moclobemide 300 mg three times daily
Number of subjects: 270

Group type: COMPARATOR
Intervention: Moclobemide 450 mg three times daily
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 270
Study: 2174312

Group type: EXPERIMENTAL
Intervention: Infused branched-chain amino acids
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 7389384

Group type: EXPERIMENTAL
Intervention: 50 mg sustained-release amitriptyline (doubled after 1 week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 75 mg maprotiline (doubled after 1 week)
Number of subjects: 40
Study: 30591028

Group type: EXPERIMENTAL
Intervention: Olaratumab (20 mg/kg, IV infusion) plus liposomal doxorubicin (40 mg/m2, IV infusion) every 4 weeks
Number of subjects: 123

Group type: COMPARATOR
Intervention: Liposomal doxorubicin (40 mg/m2, IV infusion) every 4 weeks
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Olaratumab+liposomal doxorubicin in platinum-refractory subgroup (n=15)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Liposomal doxorubicin in platinum-refractory subgroup (n=16)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Olaratumab+liposomal doxorubicin
Number of subjects: 123

Group type: COMPARATOR
Intervention: Liposomal doxorubicin
Number of subjects: 123
Study: 27013576

Group type: EXPERIMENTAL
Intervention: Global Postural Re-education (GPR)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Manual Therapy (MT)
Number of subjects: 94
Study: 24104699

Group type: EXPERIMENTAL
Intervention: Pilates exercise (1-hour lesson, 5 lessons per week for 6 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inactivity control group (normal daily activities)
Number of subjects: 60
Study: 22449319

Group type: COMPARATOR
Intervention: Intensive medical therapy alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Medical therapy plus Roux‐en‐Y gastric bypass
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Medical therapy plus sleeve gastrectomy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 150
Study: 21094362

Group type: EXPERIMENTAL
Intervention: Spironolactone, enalapril, and a β blocker (Group A)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Spironolactone and a β blocker (Group B)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Enalapril plus a β blocker (Group C)
Number of subjects: 164

Group type: COMPARATOR
Intervention: β blocker alone (Group D)
Number of subjects: 164